Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2019 | Story Leonie Bolleurs | Photo Barend Nagel
Marnus du Plooy
Marnus du Plooy, recipient of a Fulbright Scholarship, will depart for the Duke University in Durham, North Carolina, in August to complete a doctoral degree.

Marnus du Plooy will receive his master’s degree at the University of the Free State’s Winter Graduation Ceremony.

After completing his BSc degree in Microbiology, he discovered a passion for this field of research and enrolled for postgraduate studies in the Department of Microbial, Biochemical and Food Biotechnology at the UFS.

During his master’s, Du Plooy focused on the pathogenic yeasts, Cryptococcus neoformans and a related species, C. deneoformans.

Passion for science instilled at a young age

His passion for this field comes from a young age. “Both my parents were Science teachers and they instilled a love for Science in me. At school, I enjoyed the Science subjects the most and usually obtained my highest marks in these,” Du Plooy said. 

The pathogenic yeasts studied by Du Plooy, Cryptococcus neoformans and the sister species, C. deneoformans, often cause meningitis in immunocompromised individuals, such as in people living with HIV/Aids.

He pointed out: “Infection caused by these yeasts is right on the heels of TB as the second largest killer of HIV-positive patients in sub-Saharan Africa. The focus of my master’s project was to investigate new ways in which genes can be ‘switched off’ in these yeasts in order to study the role of the genes in virulence. Doing so could help to identify new drug targets for the treatment of this form of meningitis in subsequent studies.”

Expanding his international footprint

Although Du Plooy received his master’s degree from the UFS, he grabbed the opportunity to study abroad with both hands. He applied for and received a Fulbright scholarship from the Fulbright Foreign Student Programme, giving him the opportunity to study in the US.

“I did not expect to get very far with the application, as very few candidates are selected each year. I was very lucky to receive a Fulbright scholarship and an admission offer from Duke University for PhD studies in Microbiology,” said Du Plooy.

He hopes to continue with research on Cryptococcus and to contribute to improving the lives of HIV/Aids patients. “I have always been interested in pharmaceutical and medical research and noticed a need for better cryptococcal treatments, especially in sub-Saharan Africa. Cryptococcal meningitis is a neglected disease which claims more than 600 000 lives worldwide every year. The current treatment options are several decades old, with some only available in well-resourced areas.”

Du Plooy will depart for the US in August. “The duration of the degree is four to five years, where-after I will return to South Africa to apply what I have learned at home.”

News Archive

Nobel Prize-winner presents first lecture at Vice-Chancellor’s prestige lecture series
2017-11-17


 Description: Prof Levitt visit Tags: Prof Levitt visit

At the first lecture in the UFS Vice Chancellor’s Prestige Lecture series,
were from the left: Prof Jeanette Conradie, UFS Department of Chemistry;
Prof Michael Levitt, Nobel Prize-winner in Chemistry, biophysicist and
professor in structural biology at Stanford University; Prof Francis Petersen,
UFS Vice-Chancellor and Rector; and Prof Corli Witthuhn,
UFS Vice-Rector: Research. 
Photo: Johan Roux

South African born biophysicist and Nobel Prize-winner in Chemistry, Prof Michael Levitt, paid a visit to the University of the Free Sate (UFS) as part of the Academy of Science of South Africa’s (ASSAf) Distinguished Visiting Scholars’ Programme. 

Early this week the professor in structural biology at Stanford University in the US presented a captivating lecture on the Bloemfontein Campus on his lifetime’s work that earned him the Nobel Prize in 2013. His lecture launched the UFS Vice-Chancellor’s Prestige Lecture series, aimed at knowledge sharing within, and beyond our university boundaries. 

Prof Levitt was one of the first researchers to conduct molecular dynamics simulations of DNA and proteins and developed the first software for this purpose. He received the prize for Chemistry, together with Martin Karplus and Arieh Warshel, “for the development of multiscale models for complex chemical systems”.

Attending the lecture were members of UFS management, academic staff from a range of faculties and other universities as well as young researchers. “Multiscale modelling is very much based on something that makes common sense,” Prof Levitt explained. “And that is to makes things as simple as possible, but not simpler. Everything needs to have the right level of simplicity, that is not too simple, but not too complicated.”  

An incredible mind
Prof Levitt enrolled for applied mathematics at the University of Pretoria at the age of 15. He visited his uncle and aunt in London after his first-year exams, and decided to stay on because they had a television, he claims. A series on molecular biology broadcast on BBC, sparked an interest that would lead Prof Levitt via Israel, and Cambridge, to the Nobel Prize stage – all of which turned out to be vital building blocks for his research career. 

Technology to the rescue
The first small protein model that Prof Levitt built was the size of a room. But that exercise led to the birth of multiscale modelling of macromolecules. For the man on the street, that translates to computerised models used to simulate protein action, and reaction. With some adaptations, the effect of medication can be simulated on human protein in a virtual world. 

“I was lucky to stand on the shoulder of giants,” he says about his accomplishments, and urges the young to be good and kind. “Be passionate about what you do, be persistent, and be original,” he advised.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept